



May 21, 2014

## Supernus to Present at Jefferies Healthcare Conference in June

ROCKVILLE, Md., May 21, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will provide a business update and will be hosting investor meetings during the Jefferies Healthcare Conference.

Date: Wednesday, June 4  
Presentation Time: 11:00 am ET  
Place: Grand Hyatt Hotel, NYC

Investors interested in arranging a meeting during this conference should contact via email Isabel Zakoscielny at [izakoscielny@jefferies.com](mailto:izakoscielny@jefferies.com).

### About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

CONTACT: Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

301-838-2591

or

Investor Contact:

Cockrell Group

877-889-1972

[investorrelations@thecockrellgroup.com](mailto:investorrelations@thecockrellgroup.com)

[cockrellgroup.com](http://cockrellgroup.com)



Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media